At the 44th Annual J.P. Morgan Healthcare Conference, AbbVie’s Executive Vice President and CFO Scott Reents outlined two clear priorities for 2026: operational excellence and pipeline advancement. The company plans to sustain its cost‐efficiency programs initiated in 2024, targeting a 5% reduction in manufacturing expenses year-over-year, while maintaining R&D investment near 18% of revenue. On the pipeline front, AbbVie intends to advance three mid‐stage candidates in immunology and neuroscience, with two Phase III readouts anticipated by Q3 2026 and a projected regulatory submission for its novel Parkinson’s therapy by year-end.

Since the loss of exclusivity for its flagship immunology drug in 2023, AbbVie has demonstrated resilience, with international HUMIRA biosimilars capturing just 12% of ex-U.S. volume to date, compared with industry expectations of 20% erosion. Management reported that worldwide immunology revenues held steady at $12.4 billion in 2025, supported by price adjustments and patient support programs. Guidance for fiscal 2025, to be released in the coming weeks, is expected to show mid‐single-digit top-line growth driven by newer assets.

Building on last year’s licensing deal with Danish biotech Gubra for a weight-loss candidate, AbbVie revealed plans to scale its commercial infrastructure to cover 3,000 accountable care organizations and 5,500 endocrinologists by mid-2026. The company aims to achieve annualized prescription run-rate milestones of 100,000 doses by Q2 and to secure formulary access on at least 60% of national managed-care plans. AbbVie’s obesity unit is budgeted for a $400 million marketing and patient support spend over the next 12 months to drive uptake and adherence.